Cargando…

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administered into the patient with the aim to induce a tumor-specific immune response. DC vaccination...

Descripción completa

Detalles Bibliográficos
Autores principales: Bol, Kalijn F., Schreibelt, Gerty, Rabold, Katrin, Wculek, Stefanie K., Schwarze, Julia Katharina, Dzionek, Andrzej, Teijeira, Alvaro, Kandalaft, Lana E., Romero, Pedro, Coukos, George, Neyns, Bart, Sancho, David, Melero, Ignacio, de Vries, I. Jolanda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471787/
https://www.ncbi.nlm.nih.gov/pubmed/30999964
http://dx.doi.org/10.1186/s40425-019-0580-6
_version_ 1783412104604155904
author Bol, Kalijn F.
Schreibelt, Gerty
Rabold, Katrin
Wculek, Stefanie K.
Schwarze, Julia Katharina
Dzionek, Andrzej
Teijeira, Alvaro
Kandalaft, Lana E.
Romero, Pedro
Coukos, George
Neyns, Bart
Sancho, David
Melero, Ignacio
de Vries, I. Jolanda M.
author_facet Bol, Kalijn F.
Schreibelt, Gerty
Rabold, Katrin
Wculek, Stefanie K.
Schwarze, Julia Katharina
Dzionek, Andrzej
Teijeira, Alvaro
Kandalaft, Lana E.
Romero, Pedro
Coukos, George
Neyns, Bart
Sancho, David
Melero, Ignacio
de Vries, I. Jolanda M.
author_sort Bol, Kalijn F.
collection PubMed
description Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administered into the patient with the aim to induce a tumor-specific immune response. DC vaccination remains a promising approach with the potential to further improve cancer immunotherapy with little or no evidence of treatment-limiting toxicity. However, evidence for objective clinical antitumor activity of DC vaccination is currently limited, hampering the clinical implementation. One possible explanation for this is that the most commonly used monocyte-derived DCs may not be the best source for DC-based immunotherapy. The novel approach to use naturally circulating DCs may be an attractive alternative. In contrast to monocyte-derived DCs, naturally circulating DCs are relatively scarce but do not require extensive culture periods. Thereby, their functional capabilities are preserved, the reproducibility of clinical applications is increased, and the cells are not dysfunctional before injection. In human blood, at least three DC subsets can be distinguished, plasmacytoid DCs, CD141(+) and CD1c(+) myeloid/conventional DCs, each with distinct functional characteristics. In completed clinical trials, either CD1c(+) myeloid DCs or plasmacytoid DCs were administered and showed encouraging immunological and clinical outcomes. Currently, also the combination of CD1c(+) myeloid and plasmacytoid DCs as well as the intratumoral use of CD1c(+) myeloid DCs is under investigation in the clinic. Isolation and culture strategies for CD141(+) myeloid DCs are being developed. Here, we summarize and discuss recent clinical developments and future prospects of natural DC-based immunotherapy.
format Online
Article
Text
id pubmed-6471787
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64717872019-04-24 The clinical application of cancer immunotherapy based on naturally circulating dendritic cells Bol, Kalijn F. Schreibelt, Gerty Rabold, Katrin Wculek, Stefanie K. Schwarze, Julia Katharina Dzionek, Andrzej Teijeira, Alvaro Kandalaft, Lana E. Romero, Pedro Coukos, George Neyns, Bart Sancho, David Melero, Ignacio de Vries, I. Jolanda M. J Immunother Cancer Review Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor antigens and are administered into the patient with the aim to induce a tumor-specific immune response. DC vaccination remains a promising approach with the potential to further improve cancer immunotherapy with little or no evidence of treatment-limiting toxicity. However, evidence for objective clinical antitumor activity of DC vaccination is currently limited, hampering the clinical implementation. One possible explanation for this is that the most commonly used monocyte-derived DCs may not be the best source for DC-based immunotherapy. The novel approach to use naturally circulating DCs may be an attractive alternative. In contrast to monocyte-derived DCs, naturally circulating DCs are relatively scarce but do not require extensive culture periods. Thereby, their functional capabilities are preserved, the reproducibility of clinical applications is increased, and the cells are not dysfunctional before injection. In human blood, at least three DC subsets can be distinguished, plasmacytoid DCs, CD141(+) and CD1c(+) myeloid/conventional DCs, each with distinct functional characteristics. In completed clinical trials, either CD1c(+) myeloid DCs or plasmacytoid DCs were administered and showed encouraging immunological and clinical outcomes. Currently, also the combination of CD1c(+) myeloid and plasmacytoid DCs as well as the intratumoral use of CD1c(+) myeloid DCs is under investigation in the clinic. Isolation and culture strategies for CD141(+) myeloid DCs are being developed. Here, we summarize and discuss recent clinical developments and future prospects of natural DC-based immunotherapy. BioMed Central 2019-04-18 /pmc/articles/PMC6471787/ /pubmed/30999964 http://dx.doi.org/10.1186/s40425-019-0580-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Bol, Kalijn F.
Schreibelt, Gerty
Rabold, Katrin
Wculek, Stefanie K.
Schwarze, Julia Katharina
Dzionek, Andrzej
Teijeira, Alvaro
Kandalaft, Lana E.
Romero, Pedro
Coukos, George
Neyns, Bart
Sancho, David
Melero, Ignacio
de Vries, I. Jolanda M.
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
title The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
title_full The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
title_fullStr The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
title_full_unstemmed The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
title_short The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
title_sort clinical application of cancer immunotherapy based on naturally circulating dendritic cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471787/
https://www.ncbi.nlm.nih.gov/pubmed/30999964
http://dx.doi.org/10.1186/s40425-019-0580-6
work_keys_str_mv AT bolkalijnf theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT schreibeltgerty theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT raboldkatrin theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT wculekstefaniek theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT schwarzejuliakatharina theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT dzionekandrzej theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT teijeiraalvaro theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT kandalaftlanae theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT romeropedro theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT coukosgeorge theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT neynsbart theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT sanchodavid theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT meleroignacio theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT devriesijolandam theclinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT bolkalijnf clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT schreibeltgerty clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT raboldkatrin clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT wculekstefaniek clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT schwarzejuliakatharina clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT dzionekandrzej clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT teijeiraalvaro clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT kandalaftlanae clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT romeropedro clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT coukosgeorge clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT neynsbart clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT sanchodavid clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT meleroignacio clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells
AT devriesijolandam clinicalapplicationofcancerimmunotherapybasedonnaturallycirculatingdendriticcells